kentucky glp-1 side effect law firm Ozempic Lawyer in glp-1 pancreatitis law firm in
Description
The Danish firm is working toward its own oral version of Ozempic and is seeking approvals for pediatric use, which would significantly boost its addressable market
Yugueros Gonzlez A, Kanter J, Sancho A, et al
Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds)
According to Waldstein, companies should exercise caution to avoid promising drastic weight loss benefits
Given the pace of GLP-1 innovation, employer policies should remain adaptable to emerging clinical evidence and regulatory developments, such as label expansions, updated prescribing guidelines, new safety alerts, or FDA decisions regarding compounded and novel therapies
doi: 10.1111/exd.12339
